PHARMARON - Announcement from Pharmaron Chemicals (Beijing) New Drug Technology Co., Ltd. on the additional subscription of investment fund shares
PHARMARON - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Exchange”) and Hong Kong Securities Clearing Company Limited
("Hong Kong Clearing") takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness, and expressly expressly disclaims any liability for any loss arising out of or in reliance upon the whole or any part of the contents of this announcement. Ren.
Pharmaron Beijing Co., Ltd.
Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 3759)
Overseas regulatory announcement
This announcement is made by Pharmaron Chemicals (Beijing) New Drug Technology Co., Ltd. (the "Company") pursuant to the made under Rule 13.10B of the Rules Governing the Listing of Securities of Limited Company.
The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.
By order of the board of directors Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.
Chairman Dr. Lou Pak Leung
People's Republic of China, Beijing May 22, 2026
As at the date of this announcement, the board of directors includes executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employees Representative Director Mr. Li Chengzong; Non-executive Directors Mr. Li Jiaqing and Ms. Wan Xuan; Independent Non-executive Director Li Li
Ms. Hua, Professor Zeng Jinfeng and Mr. Yu Jian.
Securities code: 300759 Securities abbreviation: Pharmaron Announcement number: 2026-037
Kangkanglong Longhua Chemical ((Beijing)) New New Pharmaceutical Technology Co., Ltd.
Announcement on the additional subscription of investment fund shares
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records.
information, misleading statements or material omissions.
- Overview of investment matters
In March 2025, Pharmaron Chemicals (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the "Company")
Signed the "Limited Partnership Agreement Regarding Ningbo Yongkang Equity Investment Partnership (Limited Partnership) (Proposed)", As a limited partner, he invested RMB 100 million in Ningbo Yongkang Equity Investment Partnership (with
Limited partnership) (hereinafter referred to as "Ningbo Yongkang" or "Fund"). For details, please refer to the company’s announcement in 2025
"About Participating in Private Equity" disclosed on the cninfo.com (http://www.cninfo.com.cn) on March 20
Announcement of Investment Funds" (Announcement No.: 2025-010).
In April 2025, Ningbo Yongkang has obtained the "Business License" issued by the Ningbo Municipal Administration for Market Regulation. And completed the fund registration procedures with the Securities Investment Fund Association of China, and obtained the "Private Investment Fund Registration
Proof》. For details, please see the company’s announcement on the Juchao Information Network on April 12, 2025.
"Announcement on Progress in Participating in Private Equity Investment Funds" disclosed by (http://www.cninfo.com.cn)
(Announcement Number: 2025-023). In January 2026, the company signed the "About Ningbo Yongkang Equity Investment Partnership (Limited Partnership)"
Limited Partnership Agreement", as a limited partner, he invested an additional RMB 50 million in Ningbo Yongkang with his own funds.
currency. For details, please refer to the company’s announcement on the cninfo.com (http://www.cninfo.com.cn) on January 9, 2026.
The "Announcement on Additional Subscription of Investment Fund Shares" disclosed (Announcement No.: 2026-002).
- The progress of this additional subscription of fund shares and investment capital Recently, the company received approval from the fund manager Shanghai Hongfu Private Equity Fund Management Co., Ltd. (hereinafter referred to as
"Shanghai Hongfu"), in order to make full use of the existing industry and project resource advantages, Ningbo Yongkang plans to start
Actively expand the fund-raising work (hereinafter referred to as "this fund-raising"). After thorough research and discussion by the company’s management, the company believes that
But Ningbo Yongkang’s investment capabilities and capital management efficiency provide opportunities for better grasping the industry’s upstream and downstream market opportunities and improve
To increase the company's return on investment and promote the high-quality development of the pharmaceutical industry, the company agrees to participate in this expansion
Raise. Confirmed by the fund manager, the company invested an additional RMB 283 million in Ningbo Yongkang with its own funds.
coins (hereinafter referred to as "this additional investment") to participate in this expansion. After the completion of this additional investment, the company will Ningbo Yongkang's subscribed capital contribution totaled RMB 433 million. On May 22, 2026, the company signed
"Limited Partnership Agreement Regarding Ningbo Yongkang Equity Investment Partnership (Limited Partnership)".
This additional investment does not constitute a related transaction, nor does it constitute a
For major asset reorganizations stipulated in the Law, according to the "Shenzhen Stock Exchange GEM Stock Listing Rules"
and other relevant regulations, this investment does not need to be submitted to the company's board of directors and shareholders' meeting for review.
- Basic information of the fund
Fund name: Ningbo Yongkang Equity Investment Partnership (Limited Partnership)
Unified social credit code: 91330201MAEEWL4Y0R
Fund registration code: SAWS00
Executive Partner: Shanghai Hongfu Private Equity Management Co., Ltd. Type: Limited partnership
Registered address: Room 212-24, Building 1, No. 39 Qiyuan Road, Qianwan New District, Ningbo, Zhejiang Province
Date of establishment: March 25, 2025
Business scope: General projects: Equity investment (except for projects that require approval according to law, with a business license
Carry out business activities independently in accordance with the law). Scale of partnership: target fundraising amount of RMB 500 million (the final amount raised is
accurate). The partnership will continue to conduct market-based fundraising, and the company will strictly implement the approval process based on the fundraising situation.
procedures and timely disclosure of progress.
After the completion of this additional investment, the status of fund partners and subscribed capital contributions is as follows:
Amount of capital contribution subscribed Capital contribution subscribed Serial number Name/Title Partner category (10,000 yuan) Ratio 1 Shanghai Hongfu Private Equity Fund Management Co., Ltd. General Partner 1 0.0022% Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd. 2 Limited partners 43,300 95.1339% Ltd. 3 Yu Yuejiang Limited Partner 1,400 3.0759% Ningbo Qianwan New District Kangyuan Enterprise Management Consulting 4 limited partners 813.8118 1.7880% Partnership (limited partnership) Total - 45,514.8118 100.00% 2. Basic information of partners
(1) Fund manager
Company name: Shanghai Hongfu Private Equity Fund Management Co., Ltd.
Enterprise type: Limited liability company (natural person investment or holding) Unified social credit code: 913102303422757179
Amount of investment: RMB 10 million
Address: Room 8108, Building 1, No. 756 Yaoqiao Village South, Miao Town, Chongming District, Shanghai
Date of establishment: June 4, 2015
Private equity fund manager registration number: P1028151 Registration time: November 25, 2015
Major shareholders: Shanghai Hongfu Houde Enterprise Management Partnership (Limited Partnership) holds 45%, Yang Zhichun
Holds 30% of the equity, Ma Ji holds 20% of the equity, and Meng Guoying holds 5% of the equity.
Actual controller: Yang Zhichun
Business scope: General projects: private equity investment fund management, venture capital fund management services (required You can only engage in business activities after completing registration with the Asset Management Association of China). (Except if required by law
In addition to approved projects, business activities can be carried out independently in accordance with the law with a business license)
Shanghai Hongfu is not the person subject to execution for breach of trust and has no affiliation or other interest arrangement with the company.
The actual controller, shareholders holding more than 5% of the shares, directors, and senior managers have no related relationships or interests.
Arrangement. There is no concerted action relationship between Shanghai Hongfu and other investors participating in the fund, and there is no direct or Hold company shares indirectly.
(2) Limited partners
The other limited partners of the fund are Yu Yuejiang and Ningbo Qianwan New District Kangyuan Enterprise Management Consulting Partnership.
(Limited Partnership) information is consistent with previously disclosed information.
- Main contents of partnership agreement
This additional investment does not involve the revision of the main terms of the partnership agreement. The main terms of the partnership agreement are the same as those previously The contents disclosed are basically the same.
- Impact on the company
The company’s additional investment aims to leverage the resource advantages of professional institutions to further enhance the company’s investment capabilities.
Strengthen efforts to seize development opportunities in the biopharmaceutical industry. This additional investment will not have a substantial impact on the company, nor will it
It will not cause the company to control the fund. As a limited partner, the company does not have a single veto on fund investment decisions. decision-making power. The actual controller of the company, shareholders holding more than 5% of the shares, directors and senior managers are not in the fund.
He held the position and did not participate in the share subscription of the Fund, and there was no harm to the interests of the company and all shareholders.
This additional investment will not have a significant impact on the company's financial status and operating results in the short term. The company will
The partnership shall be recognized, measured, and accounted for in accordance with the Accounting Standards for Business Enterprises. The fund focuses on financial returns
For investment purposes, there is no horizontal competition with the company; if future cooperation matters constitute related transactions, the company will strictly
We must promptly perform decision-making approval procedures and information disclosure obligations in accordance with the requirements of relevant rules and regulations. Fund general Private equity funds and venture capital funds that want to invest in the life and health industry do not have a synergistic relationship with the company.
The company did not use the super-raised funds to permanently replenish working capital in the twelve months before this additional investment.
situation.
In the subsequent operation of the fund, there may be subsequent fundraising, fund investment, risk management and control, and investment income.
Due to various risk factors such as uncertainty and exit, the company will strictly follow relevant regulations to conduct subsequent re-investment of the fund. Major progress will be disclosed in a timely manner, and investors are advised to pay attention to investment risks.
Prepare documents for future reference
Limited partnership agreement regarding Ningbo Yongkang Equity Investment Partnership (Limited Partnership);
Other documents required by Shenzhen Stock Exchange.
Announcement is hereby made.
Board of Directors of Pharmaron Chemical (Beijing) New Drug Technology Co., Ltd.
May 22, 2026